Sakari Knuutila

Westfälische Hochschule — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

62h-index11.1kcitations366works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genomic variations and chromosomal abnormalities(58), Chronic Lymphocytic Leukemia Research(43), Cancer Genomics and Diagnostics(38), Lymphoma Diagnosis and Treatment(31), Acute Myeloid Leukemia Research(31)

Publications362 total

Correction: Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts
Gut Pathogens·2025Open Access
Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts
Gut Pathogens·2025· 4 citedOpen Access
The frequency of NRAS mutation in stool samples of Iranian colorectal cancers compared to Finnish patients
Journal of Research in Medical Sciences·2024Open Access
Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Data from Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors
2023Open Access
Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Data from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Data from Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors
2023Open Access
Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Figure 1 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Figure 5 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Data from Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors
2023Open Access
Supplementary Figure 2 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Materials and Methods, Figure Legends, Tables 1 - 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Data from Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors
2023Open Access
Data from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Figure 2 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
Supplementary Figure 3 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
2023Open Access
page 1 of 19Next →

Frequent Co-authors

Wael El‐Rifai(6), Erkki Elonen(5), Albert de la Chapelle(5), Kaarle Franssila(4), Tarja Niini(4), Gunnar Juliusson(3), David Oscier(3), Clara D. Bloomfield(3), Heikki Joensuu(3), Kari Alitalo(3), Samuli Hemmer(3), Kowan Ja Jee(3), Jaakko Hollmén(3), Yan Aalto(3), Kim Vettenranta(3), Païvi Peltomäki(3), M Fitchett(2), Matthew P. Strout(2), Tapani Ruutu(2), Michael A. Caligiuri(2)